Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Central Serous Chorioretinopathy Treatment & Management

  • Author: Kean Theng Oh, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Sep 10, 2015
 

Medical Care

Efficacy of tranquilizers or beta-blockers is unknown. Furthermore, an evaluation of 230 consecutive patients with central serous chorioretinopathy (CSCR) found that use of psychopharmacologic agents (eg, anxiolytics, antidepressants) was a risk factor for CSCR. Use of corticosteroids in the treatment of CSCR should be avoided because it may result in exacerbation of serous detachments already present.

Tatham and Macfarlane described a case series of patients who were treated with propranolol for CSCR.[38] They suggested that beta-blockade had a hypothetical mechanism in treating CSCR. Further evidence is needed to substantiate this potential treatment.

Nielsen et al proposed the use of mifepristone in the treatment of chronic CSCR in a case report.[39]

Forooghian et al evaluated the safety and efficacy of finasteride, an inhibitor of dihydrotestosterone synthesis, in 5 patients for chronic CSCR. Macular thickness and subretinal fluid decreased while treated and recurred immediately upon planned cessation of the medication.[40]

Steinle et al reported a single patient successfully treated with oral rifampin after having chronic subretinal fluid for more than 2 years’ duration. The fluid resorbed after 1 month of rifampin therapy.[41] Shulman et al conducted a prospective pilot study on 12 patients with chronic CSCR and concluded that oral rifampin may be a treatment option in patients with longstanding chronic CSCR.[42] However, a case of rifampin-induced hepatotoxicity has also been reported during treatment of CSCR.[43]

Kurup et al reported a retrospective series of 9 patients who were treated with low-dose oral methotrexate without any apparent complications and resolution of subretinal fluid.[44]

Chin et al reported a series of 120 patients who had some response to mineralocorticoid antagonists, eplerenone or spironolactone. They specifically evaluated patients with recalcitrant disease and found a positive effect in half of the patients treated.[45] Other authors have also demonstrated the potential for mineralocorticoid antagonists in the treatment of CSCR.[46, 47]

Intravitreal bevacizumab (Avastin) has been used to successfully treat the rare complication of choroidal neovascularization following CSCR.[48, 49, 50]

Anti-VEGF agents such as bevacizumab and ranibizumab are also being used to treat the neurosensory detachment of CSCR in the absence of choroidal neovascularization. Bae et al conducted a prospective randomized study comparing intravitreal ranibizumab to low-fluence photodynamic therapy in chronic CSCR. At 6 months, they concluded that the anatomic outcomes with ranibizumab injections were “not promising” compared with low-fluence photodynamic therapy.[51] . Semeraro et al compared intravitreal bevacizumab to low-fluence photodynamic therapy for treatment of chronic CSCR. The series was limited to 22 patients total and no statistical significant difference could be identified.[52]

Next

Surgical Care

Laser photocoagulation should be considered under the following circumstances: (1) persistence of a serous retinal detachment for more than 4 months, (2) recurrence in an eye with visual deficit from previous CSCR, (3) presence of visual deficits in opposite eye from previous episodes of CSCR, and (4) occupational or other patient need requiring prompt recovery of vision.

Laser treatment also may be considered in patients with recurrent episodes of serous detachment with a leak located more than 300 µm from the center of the fovea.[53, 54]

Laser treatment shortens the course of the disease and decreases the risk of recurrence for CSCR, but it does not appear to improve the final visual prognosis.[55, 56]

Some evidence suggests that patients with chronic CSCR (diffuse retinal pigment epitheliopathy) may have better prognosis with laser treatment.

Photodynamic therapy (PDT) has growing support in the literature as a treatment of chronic CSCR and, most recently, acute phases of this condition. PDT is known to have a direct effect on the choroidal circulation but was limited by potential adverse effects, such as macular ischemia. Authors, such as Lai et al, are now describing reduced dosing of verteporfin, while the use of reduced fluence has been shown to be therapeutically effective in age-related macular degeneration. The rates of adverse events have decreased significantly with these modifications.[57, 35]

Use of verteporfin and PDT was first reported in 2003 in the setting of CSCR.[58]

Yannuzzi et al described using ICG angiography to first identify areas of choroidal hyperpermeability that were then targeted with PDT.[58]

Subsequent studies, using PDT protocols established by the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study, have reported case series that support the use of PDT, especially in the setting of chronic CSCR with neurosensory detachments.

PDT is believed to hasten both fluid resorption and visual recovery.

Lai et al described the use of half dose verteporfin in the treatment of CSCR.[35] They proposed 3 mg/m2 of verteporfin infused over 8 minutes, followed 2 minutes later with ICG guided PDT. Of the eyes treated, 85% showed complete resolution of the neurosensory retinal detachment and/or pigment epithelial detachment by 1 month after treatment.

Reibaldi et al evaluated the treatment efficacy of standard-fluence PDT versus low-fluence PDT using microperimetry. The study found improvement of macular sensitivity following treatment along with greater efficacy in treatment overall using low-fluence PDT.[59]

Bae et al compared low fluence PDT to intravitreal ranibizumab in a prospective randomized trial. Although only 8 eyes were randomized to each group, ranibizumab did not appear promising when compared with low fluence PDT. After a single treatment, 6 of the 8 eyes in the PDT group had resolution of subretinal fluid whereas 4 of the 8 eyes in the ranibizumab group ultimately required PDT rescue treatment.[60]

Multiple authors have also begun to use PDT as a first-line therapy for acute focal leaks from CSCR with reported success. Most papers describe resolution of subretinal fluid within 1 month of treatment.

Chan et al demonstrated that there is evidence of choroidal vascular changes on ICG with regard to choroidal permeability and vascular remodeling.[61]

ICG mediated photothrombosis is a technique using a low-intensity laser combined with ICG dye infusion to treat focal areas of hyperpermeability in the choroid. Like PDT, it addresses treatment to the level of the choroidal vasculature.[62]

An 810-nm laser is applied after infusion of ICG dye.

Without prior ICG dye, investigators have also used the 810-nm laser as transpupillary thermotherapy (TTT) with moderate anecdotal success.[63, 64]

However, Penha et al described severe retinal thermal injury in a 31-year-old man following this treatment modality and recommended caution for this adverse event following ICG mediated TTT treatment.[65]

Previous
Next

Activity

Patient participation in stress-reducing activities (eg, exercise, meditation, yoga) is recommended.

Previous
 
 
Contributor Information and Disclosures
Author

Kean Theng Oh, MD Consulting Staff, Associated Retinal Consultants, PC

Kean Theng Oh, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Michigan Society of Eye Physicians & Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, Club Jules Gonin

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Brian A Phillpotts, MD, MD 

Brian A Phillpotts, MD, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Medical Association, National Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, James C Folk, MD, to the development and writing of this article.

References
  1. Okushiba U, Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nihon Ganka Gakkai Zasshi. 1997 Jan. 101(1):74-82. [Medline].

  2. Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. 1999 Apr. 127(4):477-8. [Medline].

  3. Marmor MF, Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol. 1999 Feb. 117(2):184-8. [Medline].

  4. Leveque TK, Yu L, Musch DC, Chervin RD, Zacks DN. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath. 2007 Dec. 11(4):253-7. [Medline].

  5. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006 Aug. 47(8):3474-8. [Medline].

  6. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002 Oct. 109(10):1834-7. [Medline].

  7. Cotticelli L, Borrelli M, D'Alessio AC, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006 Mar-Apr. 16(2):274-8. [Medline].

  8. Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo). 2012 Sep. 67(9):1047-52. [Medline].

  9. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2012 Jul 12. [Medline].

  10. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008 Jan. 115(1):169-73. [Medline].

  11. Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol. 1989 Feb. 24(1):20-3. [Medline].

  12. Matsunaga H, Nangoh K, Uyama M, Nanbu H, Fujiseki Y, Takahashi K. [Occurrence of choroidal neovascularization following photocoagulation treatment for central serous retinopathy]. Nihon Ganka Gakkai Zasshi. 1995 Apr. 99(4):460-8. [Medline].

  13. Otsuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina. 2002 Feb. 22(1):25-32. [Medline].

  14. Tsai DC, Huang CC, Chen SJ, et al. Central serous chorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br J Ophthalmol. 2012 Dec. 96(12):1484-8. [Medline].

  15. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996 Dec. 103(12):2070-9; discussion 2079-80. [Medline].

  16. Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995 Oct. 79(10):922-5. [Medline]. [Full Text].

  17. Gass JDM. Stereoscopic Atlas of Macular Disease. 4th ed. 1997. 52-70.

  18. Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Arch Ophthalmol. 1991 May. 109(5):677-81. [Medline].

  19. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994. 14(3):231-42. [Medline].

  20. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987 Summer. 7(2):111-31. [Medline].

  21. Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology. 2002 Oct. 109(10):1765-6. [Medline].

  22. Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging. 2004 Mar-Apr. 35(2):165-7. [Medline].

  23. Fraunfelder FW, Franufelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 2008. 28:606-9.

  24. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep. 48:82-118. [Medline].

  25. Breukink MB, Schellevis RL, Boon CJ, Fauser S, Hoyng CB, den Hollander AI, et al. Genomic Copy Number Variations of the Complement Component C4B Gene Are Associated With Chronic Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci. 56:5608-13. [Medline].

  26. Moschos MM, Gazouli M, Gatzioufas Z, Brouzas D, Nomikarios N, Sivaprasad S, et al. PREVALENCE OF THE COMPLEMENT FACTOR H AND GSTM1 GENES POLYMORPHISMS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2015 Aug 19. [Medline].

  27. Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996 Dec. 103(12):2081-90. [Medline].

  28. Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993 Sep. 111(9):1229-33. [Medline].

  29. Mansuetta CC, Mason JO 3rd, Swanner J, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004 Jun. 137(6):1096-100. [Medline].

  30. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999 Jul. 128(1):63-8. [Medline].

  31. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004 Feb. 111(2):244-9. [Medline].

  32. Spaide RF. Deposition of yellow submacular material in central serous chorioretinopathy resembling adult-onset foveomacular vitelliform dystrophy. Retina. 2004 Apr. 24(2):301-4. [Medline].

  33. Ooto S, Hangai M, Sakamoto A, et al. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology. 2010 Sep. 117(9):1800-9, 1809.e1-2. [Medline].

  34. Chappelow AV, Marmor MF. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch Ophthalmol. 2000 Sep. 118(9):1211-5. [Medline].

  35. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 2006 Jul. 90(7):869-74. [Medline]. [Full Text].

  36. Ozdemir H, Karacorlu SA, Senturk F, Karacorlu M, Uysal O. Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye (Lond). 2008 Feb. 22(2):204-8. [Medline].

  37. Ojima Y, Tsujikawa A, Hangai M, et al. Retinal sensitivity measured with microperimeter 1 after resolution of central serous chorioretinopathy. Am J Ophthalmol. 2008. 146:77-84.

  38. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006 Apr. 22(2):145-9. [Medline].

  39. Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina. 2007 Jan. 27(1):119-22. [Medline].

  40. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina. 2011 Apr. 31(4):766-71. [Medline]. [Full Text].

  41. Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol. 2012 Jan. 96(1):10-3. [Medline].

  42. Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015 Mar 21. [Medline].

  43. Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014 Winter. 8 (1):70-2. [Medline].

  44. Kurup SK, Oliver A, Emanuelli A, Hau V, Callanan D. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina. 2012 Nov-Dec. 32(10):2096-101. [Medline].

  45. Chin EK, Almeida DR, Roybal CN, Niles PI, Gehrs KM, Sohn EH, et al. Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol. 2015. 9:1449-56. [Medline].

  46. Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R, et al. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A Randomized Controlled Crossover Study. Retina. 2015 May 26. [Medline].

  47. Salz DA, Pitcher JD 3rd, Hsu J, Regillo CD, Fineman MS, Elliott KS, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015 Apr. 46 (4):439-44. [Medline].

  48. Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye (Lond). 2009 Feb. 23(2):488-9. [Medline].

  49. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol. 2008 Sep. 246(9):1235-9. [Medline].

  50. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007 Jun. 143(6):977-983. [Medline].

  51. Bae SH et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitrealranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011. 152:784-92.

  52. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012 Nov. 56(6):608-12. [Medline].

  53. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007 Jun. 143(6):977-983. [Medline].

  54. Watzke RC, Burton TC, Woolson RF. Direct and indirect laser photocoagulation of central serous choroidopathy. Am J Ophthalmol. 1979 Nov. 88(5):914-8. [Medline].

  55. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr. 95(4):457-66. [Medline].

  56. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997 Apr. 104(4):616-22. [Medline].

  57. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004 Jun. 137(6):1073-80. [Medline].

  58. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003 Jun. 23(3):288-98. [Medline].

  59. Reibaldi M, Boscia F, Avitabile T, et al. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Jun. 151(6):953-960.e2. [Medline].

  60. Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Nov. 152(5):784-92.e2. [Medline].

  61. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003 Dec. 87(12):1453-8. [Medline]. [Full Text].

  62. Costa RA, Scapucin L, Moraes NS, et al. Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res. 2002 Nov. 25(5):287-97. [Medline].

  63. Hussain N, Khanna R, Hussain A, Das T. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006 Aug. 244(8):1045-51. [Medline].

  64. Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond). 2008 Jan. 22(1):100-6. [Medline].

  65. Penha FM, Aggio FB, Bonomo PP. Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy. Am J Ophthalmol. 2007 May. 143(5):887-9. [Medline].

  66. Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol. 1992. 81(4):379-86. [Medline].

  67. Folk JC, Thompson HS, Han DP, Brown CK. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol. 1984 Sep. 102(9):1299-302. [Medline].

  68. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996 Jun. 114(6):689-92. [Medline].

  69. Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995 May. 102(5):737-47. [Medline].

  70. Hooymans JM. Fibrotic scar formation in central serous chorioretinopathy developed during systemic treatment with corticosteroids. Graefes Arch Clin Exp Ophthalmol. 1998 Nov. 236(11):876-9. [Medline].

  71. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003 Dec. 23(6):752-63. [Medline].

  72. Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005 Dec. 112(12):2088-94. [Medline].

  73. Yannuzzi LA, Freund KB, Goldbaum M, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology. 2000 Apr. 107(4):767-77. [Medline].

 
Previous
Next
 
Fluorescein angiography in the early recirculation phase of a patient with a localized neurosensory detachment in the macula from central serous chorioretinopathy. Note the focal hyperfluorescence.
Fluorescein angiography in the late recirculation phase of the same patient as in the image above. Note the distribution of leakage of fluorescein dye within the neurosensory detachment.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.